Pulmonx Co. (NASDAQ:LUNG) CEO Sells $197,699.46 in Stock

Pulmonx Co. (NASDAQ:LUNG) CEO Steven S. Williamson sold 27,689 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $7.14, for a total value of $197,699.46. Following the transaction, the chief executive officer now owns 194,342 shares in the company, valued at $1,387,601.88. The trade was a 12.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Pulmonx Price Performance

Shares of NASDAQ:LUNG opened at $7.48 on Friday. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40. Pulmonx Co. has a twelve month low of $5.46 and a twelve month high of $10.01. The stock’s 50 day moving average is $6.95 and its 200-day moving average is $6.94. The firm has a market capitalization of $297.67 million, a price-to-earnings ratio of -5.19 and a beta of 0.50.

Pulmonx (NASDAQ:LUNG) last issued its earnings results on Wednesday, February 19th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.12. The company had revenue of $23.77 million for the quarter, compared to analyst estimates of $22.29 million. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. Sell-side analysts forecast that Pulmonx Co. will post -1.55 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on LUNG. Citigroup restated a “neutral” rating and set a $7.50 price target (down from $17.00) on shares of Pulmonx in a report on Wednesday, December 11th. Wells Fargo & Company lowered their target price on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research report on Wednesday, December 11th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.75.

Institutional Investors Weigh In On Pulmonx

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC raised its position in Pulmonx by 1.8% in the 3rd quarter. Barclays PLC now owns 94,109 shares of the company’s stock valued at $780,000 after buying an additional 1,679 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Pulmonx by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 315,532 shares of the company’s stock valued at $2,142,000 after buying an additional 2,363 shares during the last quarter. Rhumbline Advisers raised its position in Pulmonx by 4.9% in the 4th quarter. Rhumbline Advisers now owns 53,503 shares of the company’s stock valued at $363,000 after buying an additional 2,488 shares during the last quarter. American Century Companies Inc. raised its position in Pulmonx by 8.8% in the 4th quarter. American Century Companies Inc. now owns 34,738 shares of the company’s stock valued at $236,000 after buying an additional 2,810 shares during the last quarter. Finally, 272 Capital LP purchased a new stake in Pulmonx in the 3rd quarter valued at $25,000. 91.04% of the stock is owned by hedge funds and other institutional investors.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.